The result suggests that the protein made by the gene, known as Nwd1, and other molecules it interacts with could be worthwhile targets for new MASH therapies. The scientists published their work ...

This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate primarily targeting metabolic-associated steatohepatitis (MASH) and other ...